TerminatedPhase 2

X-82 to Treat Age-related Macular Degeneration

Stopped: Interim analysis found study had achieved primary objective

United States157 participantsStarted 2015-03-16

Plain-language summary

The purpose of this study is to evaluate the safety and efficacy of X-82 in the treatment of vision loss due to wet AMD.

Who can participate

Age range50 Years

SexALL

See this in plain English?

AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.

Inclusion Criteria: * Participants mush have wet AMD which has been diagnosed and treated with anti-VEGF in one or both eyes for at least 6 months prior to joining the study and has required at least two prior injections of intravitreal (ivt) anti-VEGF at intervals of not greater than 6 weeks for the past two injections in the eye that is selected to be the study eye. * Must have demonstrated a reduction in macular fluid or macular thickness in the study eye 14 days following an anti-VEGF injection at Screening Visit 1 * Early Treatment Diabetic Retinopathy (ETDRS) Best Corrected Visual Acuity (BCVA) of 25 letters (20/320) or better in both eyes Exclusion Criteria: * Previous vitrectomy to the study eye within 30 days of Screening Visit 1 * Choroidal neovascularization (CNV) due to causes other than AMD * Proliferative diabetic retinopathy in either eye

What they're measuring

Mean Change in Visual Acuity Score From Day -1 to Week52

Timeframe: Week 52

Trial details

NCT IDNCT02348359

SponsorTyrogenex

Sponsor typeINDUSTRY

Study typeINTERVENTIONAL

Primary completion2017-12-12

Results submitted2018-05-30

View on ClinicalTrials.gov More Age-Related Macular Degeneration (AMD) trials